If this email is not displaying properly or to forward to a colleague, please View as Webpage
PCSS Breaking Records for MAT Waiver Courses Offered
PCSS has seen a huge increase in the number of MAT waiver courses in recent months, presenting numerous opportunities to address the opioid crisis. Only six months into the third year of the grant, already 416 waiver trainings have been conducted—slightly more than what was conducted for all of the second year of the grant. 

With the average training hosting 20 participants, PCSS potentially could train more than 14,000 clinicians this year alone—and this does not include those clinicians who take the course online. More than 12,800 clinicians have taken PCSS’s online course since May 2017, when PCSS began offering online courses. When the grant was first funded, the number of trainings per year was projected to be 94 [ Read more ]
Check out the PCSS Twitter Campaign: #ChooseToTreat
We are raising our voices to reach clinicians across the country and let them know about the free trainings and resources we offer at no cost to prevent, identify and treat opioid use disorder.

We are launching this four-week campaign, "Choose To Treat" to help reduce stigma associated with opioid use disorder and to promote PCSS's vast array of free resources and trainings. Make sure to follow @PCSSProjects on Twitter and feel free to retweet or add to the conversation.

If every primary care provider was trained how to prevent, identify and treat opioid use disorder, we could make a significant impact on this public health crisis. Be a part of the solution.
PCSS Trainings
American Psychiatric Association Webinar :
Tracking Drug Use Patterns
NOTE NEW Date : March 26, 2019
Time: 12:00 pm - 1:00 pm ET
Presenter: Jane C. Maxwell, PhD; Research Professor, Addiction Research Institute, The University of Texas at Austin Steve Hicks School of Social Work

Webinar description: This presentation will focus on the latest data on emerging drug trends, including opiates, cocaine, methamphetamine, cannabis, and synthetic cannabinoids. It will show trends and encourage the use of data sources that are available but not frequently seen. [Learn more]
American Society for Pain Management Nursing Webinar:
Reducing Inpatient Opioid Consumption: Creating a Therapeutic Foundation with Breakthrough Analgesia Based on Patient Function
Date: March 27, 2019
Time: 12:00 pm to 1:00 pm
Presenters: Peggy Lutz, MSN, FNP-BC, RN-BC, Service Line Director, Pain Management, Ascension Wisconsin; Chad Dieterichs, MD, Chief of Anesthesia Seton Family of Hospitals, Capitol Anesthesiology Association, Austin Texas

Webinar description: A standardized pain management plan was developed to reduce variation in prescribing, reduce opioid consumption, and individualize pain treatment while maintaining regulatory excellence. The plan provides a foundation of scheduled non-opioid analgesics, medications for neuropathic pain and opioid effect maximization, consistent use of integrative therapies, and a plan for breakthrough pain based on the patient’s ability to achieve therapeutic activity goals (TAG).  [Learn more]
News and Publications
JAMA Pediatrics

JAMA Psychiatry

SAMHSA's recording featuring national experts, local innovative programs, and readily accessible federal resources on the intersection of behavioral health and criminal and juvenile justice now available to view .

SAMHSA is seeking a Chief Medical Officer located in the Department of Health And Human Services, Substance Abuse and Mental Health Services Administration, the Office of the Assistant Secretary, Office of the Chief Medical Officer, headquartered in Rockville, Maryland . Learn more .
PCSS Online Brochure. Please share this link with colleagues: https://goo.gl/G1ay6H
Funding for this initiative was made possible (in part) by grant no. 5U79TI026556-03 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.